Absci Corp reports results for the quarter ended September 30 - Earnings Summary
Absci Corp reports results for the quarter ended September 30 - Earnings Summary
Absci Corp ABSI.OQ reported a quarterly adjusted loss of 19 cents per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of -20 cents. The mean expectation of ten analysts for the quarter was for a loss of 20 cents per share. Wall Street expected results to range from -22 cents to -19 cents per share.
Revenue fell 19.6% to $304.00 thousand from a year ago; analysts expected $727.13 thousand.
Absci Corp's reported EPS for the quarter was a loss of 19 cents.
The company reported a quarterly loss of $33.3 million.
Absci Corp shares had fallen by 6.0% this quarter and gained 190.0% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 0.1% in the last three months.
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"
Wall Street's median 12-month price target for Absci Corp is $15.00, about 32.5% above its last closing price of $10.12
This summary was machine generated from LSEG data November 12 at 03:06 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
Sep. 30 2026 | -0.20 | -0.19 | Beat |
Jun. 30 2026 | -0.20 | -0.21 | Missed |
Mar. 31 2026 | -0.21 | -0.19 | Beat |
Dec. 31 2025 | -0.19 | -0.20 | Missed |
Recent news on AbSci
See all newsAbsci Corp reports results for the quarter ended September 30 - Earnings Summary
Brief: Absci Corp Files For Mixed Shelf Size Not Disclosed - SEC Filing
Absci Q3 revenue misses estimates, net loss widens on R&D spends
Focus: Beyond the Scale: Men turn to cosmetic clinics to complete weight-loss transformation
U.S. STOCKS ON THE MOVE-Sutro Biopharma, Humacyte, CoreWeave